FBLG Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 6.69%, SMA50 -1.05%, SMA200 -43.34%). The stock’s 14-day RSI is 51.97 (neutral), while the ATR of 0.03 points to moderate volatility. The stock remains hovering near 52-week lows, trading -81.51% below its high and over 28.53% above its low. Average 10-day trading volume of 140.73 thousand shares is below the 3-month average of 201.96 thousand, indicating normal recent market interest.

FibroBiologics, Inc. Common Stock has 6.66 million shares outstanding. The public float is 6.00 million shares, elevated short interest at 1.82% of float. This equals 115.20 thousand shares. The short ratio is 1.34 days. Institutional investors hold 12.02% of the float. Insiders own 10.81%. O'HEERON PETE holds 5.96 million shares, GARCIA RUBEN A has 180.00 thousand shares and Davis Jason has 70.00 thousand shares.

FibroBiologics, Inc. Common Stock generated EPS of -$0.44 over the past year. Five-year average earnings growth is -71.11%. Wall Street analysts project EPS growth of -1.92% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $5.00. The high target offers 831.68% upside. The low target suggests 210.56% downside. The mean target is $9.60. This offers 496.27% upside. FibroBiologics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended July 31, 2026, missed forecasts by -29.03%. The prior quarter beat by -0.3%. Over the last six quarters, Apple has recorded several small beats. These include -10.0% in March 31, 2025.

FibroBiologics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.11. This means the shares are trading above this model’s fair value.

FibroBiologics, Inc. Common Stock (NASDAQ:FBLG) closed at $1.61 USD, losing -$0.12 (-6.94%) from the previous close of $1.73. The stock is currently mid-range between its 52-week high and low $0.62 and $12.40. With a market capitalization of about $3.37 million, FibroBiologics, Inc. Common Stock is classified as a micro-cap and shows market-like volatility (beta ~1.22). Key stats such as the average daily volume over the past year has been around 219.44 thousand shares, volume is running light vs its 52-week average. Headquartered in Houston, TX, FibroBiologics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Peter O'Heeron, the company employs approximately 15 people and listed since February 01, 2024. FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States.

FibroBiologics, Inc. Common Stock trades at a P/E ratio of -0.27, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.31 suggesting the stock is closer to book value. The P/FCF stands at -0.23, also above market averages.

FibroBiologics, Inc. Common Stock (NASDAQ:FBLG) shares are up 43.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows FibroBiologics, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.27. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.00, suggesting 707.45% upside. Our AI forecast model points to short-term strength (29.19% over two weeks), a medium-term fall (-76.4% over three months), and a longer-term loss (-88.82% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that FibroBiologics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 29.19%, with price expected at $2.08 by September 25, 2026, within a range of $1.93 to $2.23 3-Month Outlook: Projected fall of -76.4%, reaching $0.38 by December 10, 2026, with a range of $0.00 to $0.91. 1-Year Outlook: Projected loss of -88.82%, with price at $0.18 by September 10, 2027, within a range of $0.00 to $3.85.